

# FDA Regulation of Medical Devices Postmarket Requirements


Prof. Steven S. Saliterman

Department of Biomedical Engineering, University of Minnesota


<http://saliterman.umn.edu/>



# Medical Device Development Pathway



# Recap of Authorization Pathways



# Postmarket Requirements

- Postmarketing Surveillance and the National Evaluation System for Health Technology (NEST)
  - Postmarket Surveillance Studies (“522 Studies”)
  - Adverse Event Reporting
  - Medical Device Tracking
  - The Sentinel Initiative
  - Unique Device Identification (UDI) System

# Postmarket Surveillance Studies

- ▶ Monitors the on-going safety.
- ▶ Corrective actions
  - Changing the device labeling.
  - Changing the instructions for use.
  - Improving user training.
  - Removal of the device from the market if appropriate.
- ▶ **Issues**
  - Some foreign surveillance systems have identified serious device safety concerns sooner than in the United States.
- ▶ **Additional Benefit**
  - Understanding and measuring device innovation and cost-effectiveness

## ▶ Information sources:

- **Medical Device Reporting (MDR).**
  - *Adverse Event Reporting* within 30 Days by manufacturer.
  - Annually hundreds of thousands of reports of confirmed or possible medical device related malfunctions, serious injuries, and deaths.
- **Medical Product Safety Network (MedSun).**
  - Network of 280 US hospitals ~5,000 reports annually.
- **Post-Approval Studies** –
  - May be a condition of PMA approval.

- **522 Postmarket Surveillance Studies (Class II and III Devices).**
  - If failure may cause serious consequences.
  - If intended for significant use in pediatrics.
  - Intended to be implanted >1 year.
  - Life-supporting or sustaining outside a device user facility.
- **FDA Discretionary Studies.**
  - FDA conducts its own research
  - Use of privacy-protected data- National registry, Medicare & Medicaid, EHR and literature.
- **National Evaluation System for health Technology (NEST)**
- **Real World Data (RWD)**
  - Data collected outside of traditional clinical trials.

# Medical Device Tracking

- ▶ FDA may issue a *tracking order* for any Class II or Class III device if:
  - If failure may cause serious consequences
  - Intended to be implanted <1 year
  - Life-supporting or sustaining outside a device user facility.




# The Sentinel Initiative

- ▶ Launched in 2008
- ▶ **Postmarket risk identification system**
  - Monitoring all FDA regulated products – drugs and medical devices after they have reached the market.
  - As of 2012 there was secure access to data from ~126 million patients.
  - Health partners: academic medical centers, healthcare systems and health insurance companies.

# National Medical Device Evaluation System...

Figure 1. NMDES as a Coordinated Network of Partners



**Table 2. Objectives of the NMDES Coordinating Center**

<b>Coordinating Center Objectives</b>	<b>Description</b>
<b>Functional Objectives</b>	
<b>Optimize the cost of, access to, quality of, and sharing of data related to the evaluation of medical devices</b>	The Coordinating Center should create a coordinated network of data partners by promoting UDI adoption, standardized data sharing agreements, interoperability, and automated data collection and extraction while committing to rigorous privacy, ethical, and data security protections.
<b>Promote the adoption of best practices for device evaluation</b>	The Coordinating Center should develop a clearinghouse of best practices for evaluating the safety and efficacy of medical devices that is easily accessible to researchers and the public.
<b>Develop a transparent and streamlined process for evaluating and disseminating medical device safety and effectiveness information</b>	The Coordinating Center should promote methods for evaluating emerging safety signals and the dissemination of accurate and informative safety information to patients, clinicians, and policymakers in a responsible, timely, and accurate manner.
<b>Organizational Objectives</b>	
<b>Establish governance components for NMDES and the Coordinating Center</b>	A governing board, expert committees, and an executive director will need to be identified and selected by the Coordinating Center early on. The governing components will be critical towards setting the policy agenda for NMDES activities.
<b>Develop a sustainable business model for a national medical device evaluation system</b>	The Coordinating Center should be the central body responsible for promoting the long-term sustainability of NMDES through both public and private funding sources.

## Figure A1. Essential Uses of a National Medical Device Evaluation System

- Safety surveillance to support evidence-based decision-making, recall management, and safety communication.
  - Active safety surveillance
  - Passive safety surveillance
  - Recall management
  - Safety communication
- Activities to meet specific FDA evidentiary requirements
  - Studies to support premarket submissions
  - Post-Approval Studies
  - 522 Postmarket Surveillance Studies
  - Discretionary studies
  - Indication expansions
  - Label changes
  - Fostering appropriate shifts of premarket data collection to the postmarket setting

# Unique Device Identification



U.S. Food and Drug Administration  
Protecting and Promoting Public Health

www.fda.gov

## What is a UDI?


Found on the device label, packaging or, in some cases, on the device itself

Both in plain text and machine readable format (AIDC)



UDI = DI + PI





Qty: 1 each    Size: 20mm x 12.5mm    **REF** Z1234





(01)12345678901234 (17)140102 (11)100102 (10)A1234 (21)1234

 2014-01-02     2010-01-02    **LOT** A1234    **SN** 1234

 45°C  
UPPER LIMIT OF TEMPERATURE

 KEEP DRY



 **Manufacturer**    **CompuHyper GlobalMed, LTD**    XXX-867-5309 (USA)  
101 Innovation Drive,    XXX-555-3226 (Outside USA)  
New Sales, MD 20999-0000    <http://www.compuhypergm.com>



## Compliance Dates for UDI Requirements

Device	Label/GUDID/Date Format	Direct Mark (When Required)
Class III (including class III LS/LS) <sup>1</sup> Devices licensed under the PHS Act	September 24, 2014	Class III LS/LS devices must bear a permanent UDI by September 24, 2015  All other class III devices must bear a permanent UDI by September 24, 2016
Implantable (class II, class I & unclassified)	September 24, 2015	N/A
LS/LS <sup>1</sup> (class II, class I & unclassified)	September 24, 2015	September 24, 2015
Class II (other than I/LS/LS)	September 24, 2016	September 24, 2018
Class I or unclassified (other than I/LS/LS)	September 24, 2018	September 24, 2020

# Other Requirements

- ▶ Labeling:
  - All labels and accompanying printed matter – *including advertising.*
- ▶ Manufacturing
  - Good Manufacturing Practice (GMP) (as described in the Quality System (QS) regulations)
- ▶ Compliance and Enforcement
  - Inspection
  - Warning Letter
  - Product Recall

# Recent Literature

Clinical Review & Education

JAMA Internal Medicine | Special Communication

## Renewing the Call for Reforms to Medical Device Safety— The Case of Penumbra

Kushal T. Kadakia, MSc; Adam L. Beckman, BS; Joseph S. Ross, MD, MHS; Harlan M. Krumholz, MD, SM

**IMPORTANCE** Strengthening premarket and postmarket surveillance of medical devices has long been an area of focus for health policy makers. The recent class I recall (the most serious of the US Food and Drug Administration [FDA] recalls) of reperfusion catheters manufactured by Penumbra, a US-based medical device company, illustrates issues of device safety and oversight that mandate attention.

[← Editorial page 8](#)

[+ Supplemental content](#)



# Medical Device Recalls 2022

## Feds find new heart pump defect

The troubled Medtronic device faces fresh recall; battery failure feared.

By BURL GILYARD  
burl.gilyard@startribune.com

The U.S. Food and Drug Administration issued another

“Med  
ing a pot  
affecting  
nalbatte  
Ventric  
(HVAD)  
spokesw  
said in a  
was initi  
complai  
stopped  
failed to

Accor  
welding  
the batte  
possibly  
est recal  
the U.S.  
week in

“Med  
death a  
recall, a  
the affe  
the FDA

## Smiths Medical pumps recalled

Minnesota-made syringe infusion devices linked to 1 death, 7 serious injuries.

By BURL GILYARD  
burl.gilyard@startribune.com

These software problems led to seven serious injuries and one known death, according to the company.

Syringe pumps deliver precise amounts of blood, drugs, antibiotics and other therapeutic fluids through infusion tubing. According to the FDA recall notice, they are mostly used in neonatal and pediatric patients or operating rooms and intensive care units for adults.

Smiths Medical first issued a 15-page Urgent Medical Device Correction letter in April detailing the problems

Minneapolis Star Tribune 6/24/2022

Minneapolis Star Tribune 7/21/2022

# Medtronic calls back 1 million catheters

A single complaint spurs  
action for potential leak.

By BURL GILYARD  
burl.gilyard@startribune.com

Medtronic has recalled  
more than 1 million catheters

The company  
action was issued  
providers using  
and patients who  
tive catheter imp

“Medtronic re  
voluntary medic  
related to specific  
hemodialysis cat  
of a potential le  
tion in the cathe  
may result in u  
fluid return dur  
Pamela Lee, a s  
for Medtronic.

Hemodialysi  
when a patient’s l  
longer function r  
Lee added, “Th  
re reports of re

Minneapolis Star Tribune 8/2/2022

Minneapolis Star Tribune 9/21/2022

# Summary

- ▶ **Authorization Pathway**
- ▶ **Postmarket Requirements**
  - Postmarket Surveillance Studies.
    - Adverse Event Reporting, Medical Device Tracking, UDI (Unique Device ID)
  - National Medical Device Evaluation System.
  - Labeling and Manufacturing
  - Compliance and Enforcement
- ▶ **Medical Device Recalls 2022**